In addition to increasing the risk of premature mortality, accumulating evidence indicates that
various CPIs affect schizophrenia treatment outcomes. Thus, researchers and healthcare …

To the Editors: Maintenance antipsychotic treatment plays a crucial role to reduce the
frequencies of psychotic relapses in patients affected by schizophrenia (SCZ). 1 Longacting …

Background Tobacco smoking has been described as the main cause of chronic obstructive
pulmonary disease (COPD) and this habit is clearly more frequent among individuals with …

Objective: The aim of the study was to explore the mortality rate and the associated risks
factors in patients with schizophrenia during a10-year follow up period. Method: We …

Background Individuals with schizophrenia (SCZ) suffer from higher morbidity and mortality
than the general population. Some of this is due to concurrent somatic disease. Aims To …

The lifespan of schizophrenia (SCZ) patients is considered 25 years shorter compared to the
general population, primarily due to cardiovascular (CV) disease. This study aims to assess …

Supportive and palliative care for people with respiratory p... : Current Opinion in Supportive
and Palliative Care Supportive and palliative care for people with respiratory problems and …

Background: Long-term outcome in schizophrenia remains unsatisfactory due to continued
premature deaths and insufficient health treatment. Subjective quality of life (SQoL) …

Background: Clozapine is the gold standard medication for treatment-resistant psychosis,
with robust evidence supporting its efficacy in multiple symptom domains. However …

Objective: People with early episode psychosis (EEP) have more negative care outcomes
than do people with later episode psychosis (LEP), including higher levels of high-intensity …